IP Library Granted Patent US 12,357,648
Granted Patent B2
US 12,357,648 · App. 18/652,718 · Granted Jul 15, 2025

Injectable antibiotic formulations and use thereof

Inventors: Neil E. Paulsen (Overland Park, KS); Gail L. Dempsey (Overland Park, KS); Michael S. Daniel (Overland Park, KS); Tiffany G. Tomlinson (Overland Park, KS); Douglas I. Hepler (Overland Park, KS); Raymond Petzold (Overland Park, KS)
Assignee: Dechra Veterinary Products, LLC
A61K31/7052A61K9/0019A61K45/06A61K47/14A61K47/44
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,357,648
App. No.
18/652,718
Granted
Jul 15, 2025
Kind
B2
Abstract

Provided herein are pharmaceutically acceptable compositions containing macrolide antibiotics, in particular azithromycin. In particular, compositions containing azithromycin with low toxicity, especially for administration to felines, are provided herein.

Claims (23)

1. A pharmaceutical composition, comprising:

(i) a macrolide;

(ii) at least two solvents; and

(iii) an excipient;

wherein a first solvent is triacetin present in an amount of at least 23% w/w,

wherein a second solvent is present in an amount of about 20-60%, and

wherein no water, other than water molecules present as hydrates, is included in the composition.

2. The composition of claim 1 , wherein the second solvent is selected from the group consisting of a triglyceride, an acetylated monoglyceride, propyldicaprylates/dicaprates and caprylic/capric triglycerides.

3. The composition of claim 1 , wherein the macrolide is a mono- or di-hydrate macrolide.

4. The composition of claim 3 , wherein the macrolide is azithromycin.

5. The composition of claim 1 , wherein the triacetin is present in an amount of about 38% w/w.

6. The composition of claim 1 , wherein the excipient comprises a surfactant.

7. The composition of claim 6 , wherein the surfactant is selected from the group consisting of castor oil, hydrogenated castor oil, polyoxyl 15 hydroxystearate, polyethylene glycol 40 hydrogenated castor oil, propyl dicaprylate/dicaprate, D-α-tocopherol polyethylene glycol 1000 succinate (TPGS), polysorbate or lecithin.

8. The composition of claim 7 , wherein the surfactant is polyoxyl 15 hydroxystearate.

9. The composition of claim 7 , wherein the polyoxyl 15 hydroxystearate is present in an amount of about 1% w/w.

10. The composition of claim 2 , wherein the triglyceride is a caprylic or caprylic/capric triglyceride.

11. The composition of claim 10 , wherein the triglyceride is present in an amount of about 54.0% w/w.

12. The composition of claim 4 , wherein the azithromycin is present in an amount of about 7.0% w/w.

13. The composition of claim 1 , wherein the composition is formulated for injection.

14. A method of treating an infection in a subject weighing less than about 100 pounds, comprising administering an effective amount of a composition of claim 1 .

15. The method of claim 14 , further comprising administering an additional antibiotic.

16. The method of claim 14 , wherein the subject is a feline.

17. The method of claim 14 , wherein the composition is administered by injection.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 25, 2024
From: PAULSEN, NEIL E.; DEMPSEY, GAIL L.; DANIEL, MICHAEL S.; TOMLINSON, TIFFANY G.; HEPLER, DOUGLAS; PETZOLD, RAY
To: PIEDMONT ANIMAL HEALTH, LLC
Reel/Frame 067835/0629 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 25, 2024
From: PIEDMONT ANIMAL HEALTH LLC
To: DECHRA VETERINARY PRODUCTS , LLC
Reel/Frame 067835/0705 →
Continuity (9)
Continuation 18123811 · Mar 20, 2023
Continuation 17197838 · Mar 10, 2021
Continuation 16937094 · Jul 23, 2020
Continuation 16359197 · Mar 20, 2019
Continuation 15179625 · Jun 10, 2016
Provisional Application 62312382 · Mar 23, 2016
Provisional Application 62307284 · Mar 11, 2016
Provisional Application 62173850 · Jun 10, 2015
Related Publication 20240285662A1 · Aug 29, 2024
References Cited (24)
US 6984403B2 · Hagen et al. · 2006 [cited by applicant]
US 7108865B2 · Curatolo et al. · 2006 [cited by applicant]
US 7919522B2 · Soll et al. · 2011 [cited by applicant]
US 8710019B2 · Huber · 2014 [cited by examiner]
US 10286003B2 · Paulsen · 2019 [cited by examiner]
US 10729709B2 · Paulsen · 2020 [cited by examiner]
US 11628180B2 · Paulsen · 2023 [cited by examiner]
US 12005071B2 · Paulsen · 2024 [cited by examiner]
US 20020044965A1 · Curatolo · 2002 [cited by examiner]
US 20070293446A1 · Soll et al. · 2007 [cited by applicant]
US 20080160067A1 · Boeckh et al. · 2008 [cited by applicant]
WO WO199927906A1 · 1999 [cited by applicant]
WO WO2000059475A1 · 2000 [cited by applicant]
WO WO200207736A1 · 2002 [cited by applicant]
WO WO2005044254A1 · 2005 [cited by applicant]
WO WO2006052098A1 · 2006 [cited by applicant]
WO WO2007024719A2 · 2007 [cited by applicant]
WO WO2009013331A1 · 2009 [cited by applicant]
BASF Technical Information, “Kolliphor™ HS 15 Macrogol 15 Hydroxystearate Ph. Eur. Polyoxyl 15 Hydroxystearate USP,” Mar. 2, 2012, pp. 1-2. [cited by applicant]
Extended European Search Report and Search Opinion received for EP Patent Application No. 168083396.2, mailed Dec. 12, 2018, 7 pages. [cited by applicant]
International Preliminary Report on Patentability received for PCT Application No. PCT/US2016/036936, mailed Dec. 21, 2017, 7 pages. [cited by applicant]
International Search Report and Written Opinion received for PCT Application No. PCT/US2016/036936, mailed Sep. 7, 2016, 7 pages. [cited by applicant]
Ku et al., “Solutol HS15 as a Novel Excipient,” PharmTech, vol. 34, No. 11, Nov. 2, 2010, pp. 1-4. [cited by applicant]
Notice of Reasons for Rejection received for JP Patent Application No. 2018-516392, mailed Feb. 26, 2020, 12 pages (6 pages of English Translation and 6 pages of Original Document). [cited by applicant]